Padcev
| Chemical Name | enfortumab vedotin-ejfv |
| Dosage Form | Injectable (intravenous; 20 mg/vial, 30 mg/vial) |
| Drug Class | Monoclonal antibodies |
| System | Urinary |
| Company | Astellas Pharma Inc. |
| Approval Year | 2019 |
Indication
- Padcev is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.